Publications
Dec 1, 2024
FDA-Indexed, Backed by Science
At the core of Ethiqa XR is an innovative technology with demonstrated extended-release properties. Every vial is produced in the United States under Current Good Manufacturing Practice (cGMP) standards, ensuring regulatory compliance and the highest levels of quality, purity, and consistency.
U.S. Manufacturing
Not compounded, reliable drug delivery
cGMP-Regulated
FDA reviewed the safety and efficacy data supporting Ethiqa XR for the control of post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates and determined its designation for indexing.
Trusted Across Species
FDA-Indexed for captive rodents, ferrets, laboratory rabbits, and non-human primates.
Reliable Supply Chain
U.S.-based manufacturing
Grounded in FDA Standards
Manufacturing is conducted in accordance with cGMP regulations to ensure the highest standards of quality and compliance.
Assurance Through cGMP
Regulated and verified for compliance.
Quality
Purity and precision in every vial.
U.S. Manufacturing
Manufactured in Pennsylvania, U.S.A
Reliable Access
No stock outs and reliable delivery.
5
5 Years of proven Buprenorphine Pain Management
600 +
Serving 600+ Institutions Nationwide
72 hrs
Up to 72 Hours of Continuous Pain Relief
Excellence Across Technology & Manufacturing
Ensures researchers have uninterrupted access to high-quality analgesics while maintaining compliance, reliability. We support the highest standards of animal welfare.
Through strict adherence to FDA regulations, cGMP standards, and rigorous quality control, Ethiqa XR provides peace of mind for research teams. This approach ensures consistent results, and supports humane, effective pain management across captive rodents, ferrets, laboratory rabbits, and non-human primates.
- U.S.-based production
- No worries of a stock out
- Compliance-driven, cGMP-certified quality
- Quality You Can Trust
- Reliable Supply Chain
- cGMP Excellence
- Quality You Can Count On
Fidelis Animal Health has a commitment to regulatory excellence and supply assurance. By combining cGMP production, quality, and proactive inventory management, Ethiqa XR provides uninterrupted access to quality pain management that researchers and veterinarians can trust.
- FDA-regulated, cGMP
- Manufactured in the U.S.
- Trusted by institutions nationwide
- Quality You Can Trust
- Reliable Supply Chain
- cGMP Excellence
- Quality You Can Count On
Ethiqa XR is supported by robust inventory management systems that anticipate demand, prevent shortages, and guarantee on-time delivery. Every order ensures researchers have access to the high-quality pharmaceuticals they rely on without interruption.
- Reliable inventory oversight
- Proactive demand forecasting
- Dependable delivery assurance
- Quality You Can Trust
- Reliable Supply Chain
- cGMP Excellence
- Quality You Can Count On
Ethiqa XR is produced in the U.S. under FDA-enforced Current Good Manufacturing Practices (cGMP). These standards ensure drug identity, strength, quality, and purity through rigorous design, monitoring, and control of manufacturing operations.
- Strong quality management systems
- Reliable testing and monitoring
- Prevention of contamination and error
- Quality You Can Trust
- Reliable Supply Chain
- cGMP Excellence
- Quality You Can Count On
The FDA enforces pharmaceutical regulations to safeguard product quality. Ethiqa XR is manufactured under these strict regulatory frameworks, assuring clinicians and researchers that every vial meets the highest safety and efficacy benchmarks.
- FDA-regulated manufacturing
- Striving for the highest standards
- Compliance-driven excellence
FAQ
We’ve answered some of the most common questions about Ethiqa XR’s use, safety, and support.
See All FAQs
What is the NDC number for Ethiqa XR?
The NDC number is 86084-100-30.
How is Ethiqa XR (buprenorphine extended-release injectable suspension) 1.3 mg/mL CIII packaged?
Ethiqa XR is packaged in a 5 mL glass vial containing 3.0 mL injectable drug suspension.
What is the dosage for captive rodents, ferrets, laboratory rabbits, and non-human primates?
- Be sure to weigh each animal to calculate an accurate dose. For example, the dose for a 20-gram mouse would be a single subcutaneous injection of 0.05 mL (3.25 mg/kg body weight)
- If needed, a single dose can be repeated if needed after 72 hours in all animals.
What is the shelf life?
Ethiqa XR currently has a 36-month expiration date from the date of manufacture. The expiration date is indicated on both the vial label and carton.
For questions regarding expiration, please contact Fidelis Animal Health, Inc at 833-ETHIQAXR (833-384-4729).
How do I buy Ethiqa XR? Who do I get It from?
Ethiqa XR is currently available through:
- MWI Animal Health (phone 800.824.3703, mwiah.com)
- Covetrus (phone 855-724-3461, northamerica.covetrus.com)
- Midwest Veterinary Supply (phone 800-MIDWEST, midwestvetsupply.com)
- Patterson Veterinary (phone 800.225.7911, pattersonvet.com)
- Hanna’s Pharmaceutical Supply (phone 302.571.8761, hannapharm.com).
Ethiqa XR can be ordered by a licensed veterinarian or lab technician. If ordered by a lab technician, the use of the drug must be overseen by a licensed vet. Please visit EthiqaXR.com/ordering/ for more information.
If you have any questions or need assistance ordering product, please contact us at info@fidelisah.com
Stay Informed with Research and Support
We’re Here to Support You
Your insights matter—because animal care starts with true collaboration. Ethiqa XR is a trusted, science-backed product for the control of post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates. We are here to support you every step of the way. Connect with our team, ask questions, and stay informed. Together, we’re advancing animal welfare and raising the standard of care.
Learn More
Real people providing dedicated support
Direct access to experienced veterinary experts
Backed by rigorous, proven research data
ETH.LP.213.01.D.ALL.AL
Boxed Warning
Abuse Potential
ETHIQA XR contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse, and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of ETHIQA XR. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drugs or alcohol) or mental illness (e.g., depression).
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ETHIQA XR. Monitor for respiratory depression if human exposure to buprenorphine occurs. Misuse or abuse of buprenorphine by swallowing, snorting, or injecting poses a significant risk of overdose and death.
Accidental Exposure
Because of the potential for adverse reactions associated with accidental exposure, ETHIQA XR should only be administered by veterinarians, veterinary technicians, or laboratory staff who are trained in the handling of potent opioids. Accidental exposure to ETHIQA XR, especially in children, can result in a fatal overdose of buprenorphine.
Risks From Concurrent Misuse or Abuse with Benzodiazepines or Other CNS Depressants
Concurrent misuse or abuse of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
See HUMAN SAFETY WARNINGS for detailed information.
Important Safety Information
For Captive Rodents, Ferrets, Laboratory Rabbits, and Non-Human Primates:
Only administer Ethiqa XR® by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use in animals with pre-existing respiratory compromise.
Death has been reported when non-steroidal anti-inflammatory drugs (NSAIDs such as meloxicam and carprofen) and Ethiqa XR have been administered concomitantly in mice.
Do not house rats on wood chip-type bedding after administration of Ethiqa XR. Pica involving wood chip type bedding can be lethal.
Ethiqa XR may cause sedation, decreased blood pressure, decreased heart rate, decreased gastrointestinal mobility, and respiratory depression. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression. Animals should be monitored for signs of decreased cardiovascular and respiratory function when receiving Ethiqa XR.
The safety of Ethiqa XR has not been evaluated in pregnant, lactating, neonatal, or immune-compromised animals.
For Humans:
Not for use in humans. Keep out of reach of children and pets.
Ethiqa XR contains buprenorphine, a Schedule III controlled substance with an abuse potential similar to other Schedule III opioids, which may lead to overdose and death.
Ethiqa XR should be handled appropriately to minimize the risk of misuse, abuse, addiction, and criminal diversion, including restriction of access, the use of accounting procedures, and proper disposal methods as appropriate to the laboratory setting and as required by law.
Ethiqa XR should only be handled and administered by a veterinarian, veterinarian technician, or laboratory staff trained in the handling of potent opioids. Wear protective clothing when administering Ethiqa XR to avoid direct contact with human skin, eyes, oral, or other mucus membranes which could result in absorption of buprenorphine and adverse reactions.
For more information, consult the Prescribing Information including the Boxed Warning.
SA.EthiqaXR.060.05.2024